|
|
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.amarincorp.com/news.cfm Email: investor.relations@amarincorp.com |
Phone: (415) 389-4920 FAX: |
| Amarin Corporation plc (Amarin) is a neuroscience company focused on the research, development and commercialization of drugs for the treatment of central nervous system disorders. The Company's main pipeline product, Miraxion is in Phase III development for Huntington's disease and in Phase II development for depression. Amarin's other product candidates include LAX-201 and LAX-202, both under Phase II clinical trials for the treatment of depression. In February 2004, Amarin sold its United States-based subsidiary, Amarin Pharmaceuticals, Inc. and a majority of its United States products to Valeant Pharmaceuticals International. On October 8, 2004, Amarin acquired Amarin Neuroscience Limited (formerly Laxdale Limited), a privately owned neuroscience development company based in Stirling, Scotland. More | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.bioaobo.com/ Email: aobo@biosly.com Contact: Zenith Petroleum Corporation BO |
Phone: 949-443-2350 FAX: 620-662-6861 |
| American Oriental Bioengineering, Inc. (AOBO) is engaged in the development and production of bioengineered products and traditional Chinese medicinal products through its subsidiary, Harbin Three Happiness Bioengineering Co., Ltd. (Harbin Bioengineering). During the year ended December 31, 2004, AOBO expanded its product mix and categories through acquiring Heilongjiang Songhuajiang Pharmaceutical Limited (HSPL). HSPL focuses on Chinese herbal medicinal products in the form of injection powder, pills, capsules and oral liquid. Harbin Engineering's products are divided into Health Food Product Series, Chinese Herbal Medicinal Products Series and Soybean Protein Peptide Product Series. The Health Food Product Series includes compound bio-functional beverage series that is derived from honey products, marine plants and natural herbs. The iodine bio-functional beverage series are compound bio-functional beverage with iodine additives to enhance its health function. | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.biotechltd.com Email: Contact: Gale V Belding EX VP/DIR |
Phone: 604-736-3351 FAX: 212-753-0731 |
| Biotech Holdings, Ltd. researches, develops, manufacturers, and markets pharmaceutical, personal care and health care products. The Company markets DIAB II which is a new drug treatment for Type II Diabetes. The Company's manufacturing facility in British Columbia manufactures OTC creams, lotions, gels and salves for retail customers. | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.dragonbiotech.com Email: shaun@dragonbiotech.com Contact: Phillip Yuen Yiu Pak DIR |
Phone: (604) 669-8817 FAX: (604) 669-4243 |
| Dragon Pharmaceutical Inc. (Dragon) is a pharmaceutical and biotechnological company, whose business is to develop, manufacture and market pharmaceutical products in China and developing countries. Through the Company's wholly owned drug manufacturing company, Nanjing Huaxin Bio-pharmaceutical Co., Ltd. (Nanjing Huaxin) located in Nanjing City, China, Dragon manufactures and sells Erythropoietin (EPO). Products under development are a slow-release EPO and the granulocyte-colony stimulating factor (G-CSF). Dragon completed the acquisition of Oriental Wave Holding Ltd., on January 12, 2005, transforming the Company into a pharmaceutical company with three key business units consisting of a Biotech Division for biotech products, a Chemical division for bulk pharmaceutical chemical and a Pharma division for formulated drugs. | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.genemax.com/ Email: info@genemax.com Contact: Grant Atkins DIR/XCFO |
Phone: 604-331-0400 FAX: 604-331-0877 |
| GeneMax Corp. is a biotechnology company that focuses its energy in finding cures for diseases through immunotherapy technologies. | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.generex.com/ Email: info@generex.com |
Phone: (416) 364-2551 FAX: (416) 364-9363 |
| Generex Biotechnology Corporation is engaged primarily in the research and development of drug delivery technologies. The Company's primary focus is the development of its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The Company's buccal delivery technology involves the preparation of a formulation in which an active pharmaceutical agent is placed in a solution with a combination of absorption enhancers and other excipients classified generally recognized as safe (GRAS) by the United States Food and Drug Administration (FDA) when used in accordance with specified quantity and other limitations. The resulting formulation is aerosolized with a pharmaceutical grade chemical propellant and is administered to the patient using the Company's RapidMist device. More | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.hctech.com/ Email: contact@hctech.com |
Phone: (212) 736-9224 FAX: (212) 736-9008 |
| Healthcare Technologies Ltd. develops, manufactures and markets clinical diagnostic test kits and provides services and tools to diagnostic and biotech research professionals in laboratory and point of care sites in Israel and worldwide. The Company also produces and markets molecular biology based gene screening tools for the detection of certain gene-associated disorders in humans, including prenatal testing for diseases, such as cystic fibrosis, gaucher and other diseases and testing for predisposition to diseases, such as breast, ovarian and colon cancer, thrombosis and certain cardiovascular diseases. In addition, through its investment in Procognia (Israel), Healthcare Technologies has been involved in the design of glycobiology-based tools for treatment discovery and development and bioinformatics. The manufacturing activities of the Company are primarily conducted by Savyon Diagnostics Ltd. (formerly Pronto Technologies Ltd.). More | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.kvpharma.com Email: cbiffignani@kvpharmaceutical.com |
Phone: (314) 645-6600 FAX: (314) 645-6732 |
| K-V Pharmaceutical Company is an integrated specialty pharmaceutical company that develops, acquires, manufactures and markets technologically distinguished branded and generic-non-branded prescription pharmaceutical products. The Company has a range of dosage form capabilities, including tablets, capsules, creams, liquids and ointments. It conducts its branded pharmaceutical operations through Ther-Rx and its generic-non-branded pharmaceutical operations through ETHEX. Through Particle Dynamics, the Company also develops, manufactures and markets technologically advanced, value-added raw material products for the pharmaceutical, nutritional, personal care, food and other markets. More | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.nymox.com Email: info@nymox.com |
Phone: (514) 332-3222 FAX: (514) 332-2227 |
| Nymox Pharmaceutical Corporation is engaged in the research and development of therapeutics and diagnostics for the aging population with an emphasis on Alzheimer's disease. Nymox has two subsidiaries: majority-owned Serex, Inc. and wholly owned Nymox Corporation. Nymox Corporation operates the Company's clinical reference laboratory where its AlzheimAlert, a diagnostic test for Alzheimer's disease is performed. It also conducts some research and development. Serex conducts research and development, as well as some of the manufacturing for NicAlert and TobacAlert, which are used to detect a person's usage or exposure to tobacco products and second hand smoke. More | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.oncolyticsbiotech.com/ Email: dougballonc@aol.com |
Phone: (403) 670-7374 FAX: (403) 283-0858 |
| Oncolytics Biotech Inc. is a development stage company that focuses on the discovery and development of oncolytic viruses for the treatment of cancers. The lead product being developed by the Company may represent a treatment for certain tumor types and some cellular proliferative disorders. The product is a virus that is able to replicate specifically in, and hence kill, certain tumor cells both in tissue culture, as well as in a number of animal models. Oncolytics Biotech is also assessing the potential opportunities for product candidates resulting from issued patents received for Ras targeted adenovirus and herpes virus. On October 29, 2003, the Company announced the approval by the Drug Development Group of the Division of Cancer Treatment and Diagnosis, United States National Cancer Institute for multiple clinical trials to evaluate the efficacy of REOLYSIN in a range of cancers. More | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.pluristem.com Email: info@pluristem.com Contact: Harvey Lawson TR/SEC/DIR/XCEO/XCFO/ |
Phone: 011-972-4-850-1080 FAX: 011-972-4-850-1085 |
| Pluristem Life Systems Inc. is a biotechnology company dedicated to the development of stem cell expansion technology. The Company is concentrating on the expansion of cord blood hematopoietic stem cells and may provide, upon successful development and regulatory approval, critical cell expansion services to blood banks and transplants centers in the U.S. and Europe. | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.polydex.com Email: linda@northarm.com |
Phone: (416) 755-2231 FAX: (416) 755-0334 |
| Polydex Pharmaceuticals Limited is engaged in the research, development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. Polydex also manufactures bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry. The Company focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate, and other specialty chemicals. It conducts its business operations through its subsidiaries. The Company conducts its business operations through its subsidiaries, which operate as strategic business units: Dextran Products Ltd and Chemdex Inc. More | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.pranabio.com/ Email: info@pranabio.com |
Phone: FAX: |
| Prana Biotechnology Limited develops therapeutic drugs designed to treat the underlying causes of brain and eye degeneration as a result of the aging process. The Company develops therapies for a broad spectrum of age-related diseases initially focused on Alzheimer's disease. The Company's initial product, PBT-1, is a therapeutic treatment for Alzheimer's disease. In August 2003, the Company announced a new lead metal protein attenuating compound (MPAC) molecule for Alzheimer's disease designated as PBT-2 that had been selected to enter development. PBT-2 has undergone preclinical in-vitro and in-vivo testing and has been designed to have an improved safety and efficacy profile compared to PBT-1. More | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.procyte.com Email: Contact: Robin L Carmichael VP |
Phone: 425-869-1239 FAX: (212) 779-3241 |
| ProCyte Corporation is a healthcare products company that develops, manufactures and markets products for skin health, hair care, tissue repair and wound care. The Company's products include a comprehensive therapeutic skin care line including products for post-laser treatment and anti-aging applications, as well as products for thinning hair. Products incorporate the Company's patented, clinically proven copper peptide technology, which are marketed both directly and through distribution partners. | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.shire.com/ Email: ir@ca.shire.com |
Phone: FAX: |
| Shire Pharmaceuticals Group plc is a global pharmaceutical company with a strategic focus on meeting the needs of the specialist physician. The Company has a particular interest in therapies that are prescribed by specialist doctors as opposed to primary care physicians. Shire is focusing on the development of late stage projects and marketing products in the areas of central nervous system, gastrointestinal and renal. In addition to product sales, Shire generates revenues from royalties received on products that have been out-licensed to third parties. Geographically, the Company has operations in North America and Europe. More | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.swissmedica.com/ Email: djones@swissmedica.com Contact: Raghu Kilambi PR/CEO/CFO/DIR |
Phone: 416-868-0202 FAX: 416-868-6776 |
| Swiss Medica Inc. commercializes proprietary bioscience products that relieve chronic ailments. | |
.
.
.
First || Last || Next || Prev || TOP || HOME PAGE || Company Index
| Web: http://www.trinitybiotech.ie/ Email: info@trinitybiotech.com |
Phone: (800) 603-8076 FAX: |
| Trinity Biotech plc develops, manufactures and markets diagnostic test kits used for the clinical laboratory and point-of-care segments of the diagnostic market. These test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders and autoimmune disorders. The Company markets over 500 different diagnostic products in 80 countries. Trinity Biotech's product areas can be broken down under the headings of the six key technologies: Enzyme Immunoassays, Haemostasis, Fluorescence Assays, Rapid Assays, Western Blot Assays and Clinical Chemistry. More | |
.
.
.
.
.
.
(c) 2005 -- www.goldmood.com
.
.
.
.
.
.
.
.
.
.
.
06/04/2005 02:20:28
